(Total Views: 455)
Posted On: 03/18/2020 8:21:36 AM
Post# of 149086
Yes, we are 10 days from the hockey stick curve growth. I think we did slow it down and that was long enough to get some good data from others on how to proceed and slow the mortality (like Chloroquine) and slow the impact on the system. Time will tell very soon.
To the rest of the board, my apologies for not posting sooner (limited posts) and for not finding the GVHD trial. I mistakenly assumed I could search leronlimab and find them all, nope. Here is what I discovered, Leronlimab will get 3 hits, Cytodyn gets 14 hits, pro 140 gets 29 hits, and Vyrologix gets zero hits. Some think .gov is a waist of time, of course, I think those folks are defending the indefensible failures of the company to get it together. NP apparently would rather pump the story with $20k payments to proactive instead of tending the knitting and updated trials and getting press releases correct on basics like trial protocols requiring carbo in combo. They pay Amerex a lot of money for what? So the trials are not updated for months at a time? I am long about 1,200 shares of hard earned money and hoping to keep it at the very least...
I suspect we will see a deal overseas asap, compassionate use asap, IND confirmed asap, and the coup de grace will be a finance deal a few weeks after all that. BLA is a bid deal, the delays are very troubling. And the double blind placebo is a 2:1 ratio of leronlimab:placebo. This is rare and is only being used to help patients get the drug. It is harder on the company to prove efficacy. Unequal randomization (e.g. 2:1 or 3:1) is done quite rarely. There are some occasions when it is justified. Such a randomization needs to overcome scientific and ethical problems like ARDS lung damage if the patients don't get the drug.
Peace out
To the rest of the board, my apologies for not posting sooner (limited posts) and for not finding the GVHD trial. I mistakenly assumed I could search leronlimab and find them all, nope. Here is what I discovered, Leronlimab will get 3 hits, Cytodyn gets 14 hits, pro 140 gets 29 hits, and Vyrologix gets zero hits. Some think .gov is a waist of time, of course, I think those folks are defending the indefensible failures of the company to get it together. NP apparently would rather pump the story with $20k payments to proactive instead of tending the knitting and updated trials and getting press releases correct on basics like trial protocols requiring carbo in combo. They pay Amerex a lot of money for what? So the trials are not updated for months at a time? I am long about 1,200 shares of hard earned money and hoping to keep it at the very least...
I suspect we will see a deal overseas asap, compassionate use asap, IND confirmed asap, and the coup de grace will be a finance deal a few weeks after all that. BLA is a bid deal, the delays are very troubling. And the double blind placebo is a 2:1 ratio of leronlimab:placebo. This is rare and is only being used to help patients get the drug. It is harder on the company to prove efficacy. Unequal randomization (e.g. 2:1 or 3:1) is done quite rarely. There are some occasions when it is justified. Such a randomization needs to overcome scientific and ethical problems like ARDS lung damage if the patients don't get the drug.
Peace out
(1)
(0)Scroll down for more posts ▼
